Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Sep 2, 2026
Reporting period
Not applicable
Filed with the SEC
Sep 4, 2026
OfficerOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-382456
Filed / recorded
Sep 4, 2026, 5:02 AM UTC
Added to OQRO
Oct 6, 2026, 7:14 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
CORCEPT THERAPEUTICS INC
Issuer CIK
1088856
Ticker
CORT
Reporting person
Roberto Wandenkolk Vieira
Relationship
Officer
Officer title
President, Oncology
Security
Stock option (right to buy)
Table
Derivative (Table II)
Transaction date
Sep 2, 2026
Transaction code
M
Shares / units
58,333
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
141,667
Ownership form
Direct
Amendment
No
Footnotes from the filing
Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.